CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Soft Tissue Sarcoma
Special Reports in Personalized Cancer Care
Online Continuing Education Activities
SELECT A TOPIC
Urologic Oncology Videos
Return to editingDr. Oh on the Sequencing of New Therapies for Prostate Cancer
William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses sequencing of new therapies for castration-resistant prostate cancer (CRPC).
Dr. Linehan on Genes With Predisposition to Kidney Cancer
W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses genetic conditions with predisposition for patients with kidney cancer.
Dr. Tagawa on Updated Results of TAXYNERGY Trial in Prostate Cancer
Scott T. Tagawa, MD, Weill Cornell Medicine, discusses the updated results of a prospective biomarker anaylsis from the TAXYNERGY trial in patients with metastatic castration-resistant prostate cancer (mCRPC).
Dr. Saad on Apalutamide Combination for Castration-Resistant Prostate Cancer
Fred Saad, MD, University of Montreal Hospital Centers, discusses the safety and efficacy of the apalutamide combination for patients with metastatic castration-resistant prostate cancer.
Dr. McDermott on IMmotion150 Trial in RCC
David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the recent IMmotion150 trial in Renal Cell Carcinoma (RCC).
PARP Inhibitors in BRCA1/2-mutated Patients in Prostate Cancer
Panelists Raoul S. Concepcion, MD; Ashley E. Ross, MD, PhD; Jorge A. Garcia, MD; and Alicia K. Morgans, MD, MPH, discuss the use of PARP inhibitors in BRCA1- and BRCA2-mutated patients with prostate cancer.
Key Issues Surrounding the Treatment of Prostate Cancer
Dr. Oh Discusses the Role of Chemotherapy in Prostate Cancer
William K. Oh, MD, professor, Mount Sinai Hospital, discusses the current role of chemotherapy in the treatment of patients with prostate cancer.
Dr. Saad on Radium-223 for Prostate Cancer
Fred Saad, MD, professor and chief of Urology, Director of Genitourinary Oncology at the University of Montreal Hospital Centers, discusses radium-223 dichloride (Xofigo) for patients with prostate cancer.
Josh Armenia on Impact of Mutated Gene Analysis in Prostate Cancer
Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the impact of a gene mutation analysis study in prostate cancer.
Dr. Saad on Recent Updates in Active Surveillance in Prostate Cancer
Fred Saad, MD, professor and chairman of Urology, director of Genitourinary Oncology, the University of Montreal Hospital Centers, discusses recent updates in active surveillance for patients with prostate cancer.
2017 Genitourinary Cancers Symposium
Next Page >>
FDA Approval Sought in ALL, Early 2017 GU Symposium Highlights, and New HHS Secretary Confirmed
FDA Approves Maintenance Lenalidomide for Myeloma
Novel Compound GPX-150 Shows Promise in Soft Tissue Sarcoma
Specialty Pharmacy: Build, Buy, or Partner
Dendritic Immunotherapy Falters in Phase III RCC Trial
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2017
Intellisphere, LLC. All Rights Reserved.